17 Jan 2020 --- Clinical trials for two separate omega 3 products have encountered major obstacles in their search for conclusive results. Following the discontinuation of a trial for AstraZeneca’s omega 3 carboxylic acids – dubbed Epanova – the company anticipates a write-down of up to US$100 million relating to inventories, which could impact its core earnings in the fourth quarter of 2019. Meanwhile, Acasti Pharma’s TRILOGY 1 Phase 3 Trial of CaPre – an omega 3 phospholipid – found no statistical significance. This has been attributed to an unusually large placebo effect, with further analysis underway.
